How can someone legally access psychedelic therapy in Canada? This is the question that I ask David Harder, Founder and Co-CEO of ATMA.

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:

Not only will this be your chance to meet me, but also the legendary Paul Stamets!

Join our Newsletter (scroll to the bottom of the page and sign up):…

Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight

Follow us on Instagram:

To learn more about the emerging psychedelic industry, visit:

Psychedelic Spotlight

By now, most people watching this video are probably aware of the potential for psychedelic medicines, when combined with therapy, such as psilocybin and MDMA to treat a variety of mental health conditions. But receiving this treatment is still difficult.

In Canada, in addition to clinical trials, there are a couple of avenues that a patient can go through to receive psychedelic therapy. The first is called the Section 56 exemption, which has allowed dozens of people suffering from anxiety relating to terminal illnesses to undergo psilocybin therapy.

There is also a new avenue called the Health Canada “Special Access Program”, though relatively few people have gone through that route so far.

In the interview, we also discuss David’s company, ATMA. ATMA is a company that trains therapists to conduct psychedelic therapies. They also conduct therapy themselves.

Lastly, we discuss the upcoming Catalyst Psychedelic conference, happening in Kingston, Ontario between May 20-23rd. I will be there, and I hope to see you also!

Similar Posts